EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudieOpen Access · CC BY-NC-ND 4.0

Comparative evaluation of anti-inflammatory and antioxidant effects of prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention: A prospective cohort study

Shanmugapriya Vinayagam, Niti Mittal, Ashwani Kumar, Manjulata Kumawat, Aparna Parmar, Vijay Kalra, Joshuah Jebaraj

Indian Journal of Pharmacology · 2026

DOI: 10.4103/ijp.ijp_3_26 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Indian Journal of Pharmacology, 2026. Verfasst von Shanmugapriya Vinayagam und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India. Hauptthemen laut MEDLINE: Prasugrel Hydrochloride, Clopidogrel, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: While both clopidogrel and prasugrel inhibit platelet aggregation, their comparative pleiotropic effects on inflammatory and oxidative stress markers remain unclear. OBJECTIVE: To compare the anti-inflammatory and antioxidant potential of clopidogrel and prasugrel given as dual antiplatelet therapy (DAPT) along with aspirin in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). SUBJECTS AND METHODS: In this prospective cohort study, patients aged 18–65 years undergoing PCI for ACS and eligible candidates for DAPT were included. The two study groups were: aspirin + clopidogrel (AC group; n = 52) and aspirin + prasugrel (AP group; n = 52). A change in inflammatory (high-sensitivity C-reactive protein [hs-CRP]) and oxidative stress (total antioxidant capacity [TAOC]) markers at 4 weeks was compared to baseline in two groups. RESULTS: A total of 90 patients (46 in AC group and 44 in AP group) completed the study and were included in the analysis. AP group demonstrated a significantly greater reduction in hs-CRP levels at 4 weeks compared to AC group (−7.17 ± 5.95 in AP vs. −4.10 ± 3.81 mg/L in AC groups, P = 0.002). A relatively greater increase in TAOC was also seen in AP group though statistically insignificant (184.25 ± 274.03 in AP vs. 126.67 ± 198.49 in AC groups, P = 0.117). Bleeding and adverse events were comparable in two groups. CONCLUSIONS: Prasugrel-based DAPT showed significantly greater reduction in inflammation compared to clopidogrel-based DAPT, with comparable antioxidant benefit and hematological safety indicating a greater pleiotropic benefit of prasugrel than clopidogrel.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prasugrel HydrochlorideClopidogrelPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsAntioxidantsAcute Coronary SyndromeAnti-Inflammatory AgentsHumansMiddle AgedMaleFemaleProspective StudiesAdultC-Reactive ProteinAgedAdolescentAspirinOxidative StressYoung Adult

Stichwörter der Autor:innen

Dual antiplatelet therapyhigh-sensitivity C-reactive proteinpercutaneous coronary interventionpleiotropic effecttotal antioxidant capacity

Substanzen

Prasugrel HydrochlorideClopidogrelPlatelet Aggregation InhibitorsAntioxidantsAnti-Inflammatory AgentsC-Reactive ProteinAspirin

Autor:innen und Institutionen

  • Department of Pharmacology, Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India.
  • Department of Cardiology, Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India.
  • Department of Biochemistry, Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India.
  • Department of Microbiology, Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India.
  • Department of Physiology, University College of Medical Sciences and GTB Hospital, Delhi, India.

Zitieren

APA

Vinayagam, S., Mittal, N., Kumar, A., Kumawat, M., Parmar, A., Kalra, V., & Jebaraj, J. (2026). Comparative evaluation of anti-inflammatory and antioxidant effects of prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention: A prospective cohort study. Indian Journal of Pharmacology. https://doi.org/10.4103/ijp.ijp_3_26

Vancouver

Vinayagam S, Mittal N, Kumar A, Kumawat M, Parmar A, Kalra V, et al. Comparative evaluation of anti-inflammatory and antioxidant effects of prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention: A prospective cohort study. Indian Journal of Pharmacology. 2026. doi:10.4103/ijp.ijp_3_26

BibTeX
@article{Vinayagam2026,
  author = {Vinayagam, Shanmugapriya and Mittal, Niti and Kumar, Ashwani and Kumawat, Manjulata and Parmar, Aparna and Kalra, Vijay and Jebaraj, Joshuah},
  title = {Comparative evaluation of anti-inflammatory and antioxidant effects of prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention: A prospective cohort study},
  journal = {Indian Journal of Pharmacology},
  year = {2026},
  doi = {10.4103/ijp.ijp_3_26}
}
Kostenlos starten →